Brain Metastases

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2002 Jun 12

PMID 12057152

Citations 20

Authors

P Y Wen

J S Loeffler

Affiliations

Soon will be listed here.

Abstract

Brain metastases are an increasingly common complication in patients with systemic cancer. The optimal treatment for each patient depends on careful evaluation of several factors: the location, size, and number of brain metastases; the patient's age, general condition, and neurologic status; and the extent of systemic cancer to name a few. For patients with a single brain metastasis and limited systemic disease, the standard treatment is surgical resection followed by whole brain radiation therapy. In patients with a small, single metastasis, stereotactic radiosurgery is probably comparable to surgery. Patients with several metastases (up to three) and controlled systemic disease can be treated with whole-brain radiation and stereotactic radiosurgery. Patients with multiple metastases (more than three) are generally treated with whole-brain radiation alone. Radiosurgery is effective in treating patients with a limited number of recurrent brain metastases and stable systemic diseases. Surgery may have a role in patients with a large symptomatic recurrent lesion producing mass effect. Reirradiation and chemotherapy may have a limited role in patients with multiple recurrent metastases.

Citing Articles

Exposed Phosphatidylserine as a Biomarker for Clear Identification of Breast Cancer Brain Metastases in Mouse Models.

Wang L, Zhao A, Arledge C, Xing F, Chan M, Brekken R Cancers (Basel). 2024; 16(17).

PMID: 39272945 PMC: 11394599. DOI: 10.3390/cancers16173088.

Stereotactic Radiosurgery in the Management of Brain Metastases: A Case-Based Radiosurgery Society Practice Guideline.

Ladbury C, Pennock M, Yilmaz T, Ankrah N, Andraos T, Gogineni E Adv Radiat Oncol. 2024; 9(3):101402.

PMID: 38292892 PMC: 10823095. DOI: 10.1016/j.adro.2023.101402.

Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT?.

Wei X, Luo P, Chen X, Wang Z, Xu L, Xie H Thorac Cancer. 2022; 13(23):3304-3309.

PMID: 36226869 PMC: 9715792. DOI: 10.1111/1759-7714.14686.

Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?.

Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A J Immunother Cancer. 2021; 9(4).

PMID: 33827904 PMC: 8031689. DOI: 10.1136/jitc-2020-002038.

Fucosyltransferase 4 and 7 mediates adhesion of non-small cell lung cancer cells to brain-derived endothelial cells and results in modification of the blood-brain-barrier: in vitro investigation of CD15 and CD15s in lung-to-brain metastasis.

Jassam S, Maherally Z, Ashkan K, Pilkington G, Fillmore H J Neurooncol. 2019; 143(3):405-415.

PMID: 31104223 PMC: 6591197. DOI: 10.1007/s11060-019-03188-x.

References

Cooper J, Steinfeld A, Lerch I . Cerebral metastases: value of reirradiation in selected patients. Radiology. 1990; 174(3 Pt 1):883-5. DOI: 10.1148/radiology.174.3.2305074. View

Muacevic A, Kreth F, Horstmann G, Schmid-Elsaesser R, Wowra B, Steiger H . Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg. 1999; 91(1):35-43. DOI: 10.3171/jns.1999.91.1.0035. View

Del Rowe J, Bello J, Mitnick R, Sood B, Filippi C, Moran J . Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 1999; 43(1):89-93. DOI: 10.1016/s0360-3016(98)00374-5. View

Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M . Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology. 1999; 212(3):755-9. DOI: 10.1148/radiology.212.3.r99se10755. View

Schultheiss T, Kun L, Ang K, Stephens L . Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995; 31(5):1093-112. DOI: 10.1016/0360-3016(94)00655-5. View

Franciosi V, COCCONI G, Michiara M, Di Costanzo F, Fosser V, Tonato M . Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999; 85(7):1599-605. View

Noordijk E, Vecht C, Haaxma-Reiche H, Padberg G, Voormolen J, Hoekstra F . The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994; 29(4):711-7. DOI: 10.1016/0360-3016(94)90558-4. View

Vecht C, Haaxma-Reiche H, Noordijk E, Padberg G, Voormolen J, Hoekstra F . Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993; 33(6):583-90. DOI: 10.1002/ana.410330605. View

Ram Z, Culver K, Oshiro E, Viola J, DeVroom H, Otto E . Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997; 3(12):1354-61. DOI: 10.1038/nm1297-1354. View

10.

Johnson F, Harrison B, McKirgan L, Raju P, Roy T, Virgo K . A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases. Int J Oncol. 1998; 13(4):801-5. View

11.

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

12.

Rustin G, Newlands E, Begent R, Dent J, Bagshawe K . Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol. 1989; 7(7):900-3. DOI: 10.1200/JCO.1989.7.7.900. View

13.

Young R . Radiosurgery for the treatment of brain metastases. Semin Surg Oncol. 1998; 14(1):70-8. DOI: 10.1002/(sici)1098-2388(199801/02)14:1<70::aid-ssu9>3.0.co;2-#. View

14.

Schulder M, Black P, Shrieve D, Alexander 3rd E, Loeffler J . Permanent low-activity iodine-125 implants for cerebral metastases. J Neurooncol. 1997; 33(3):213-21. DOI: 10.1023/a:1005798027813. View

15.

Malacarne P, Santini A, Maestri A . Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology. 1996; 53(3):210-3. DOI: 10.1159/000227562. View

16.

Buckner J . The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Cancer Metastasis Rev. 1991; 10(4):335-41. DOI: 10.1007/BF00554795. View

17.

Clouston P, DeAngelis L, Posner J . The spectrum of neurological disease in patients with systemic cancer. Ann Neurol. 1992; 31(3):268-73. DOI: 10.1002/ana.410310307. View

18.

Schaefer P, Budzik Jr R, Gonzalez R . Imaging of cerebral metastases. Neurosurg Clin N Am. 1996; 7(3):393-423. View

19.

Slivka A, Wen P, Shea W, Loeffler J . Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993; 94(2):216-9. DOI: 10.1016/0002-9343(93)90187-t. View

20.

Glantz M, Cole B, Forsyth P, Recht L, Wen P, Chamberlain M . Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 54(10):1886-93. DOI: 10.1212/wnl.54.10.1886. View